

Study with the several resources on Docsity
Earn points by helping other students or get them with a premium plan
Prepare for your exams
Study with the several resources on Docsity
Earn points to download
Earn points by helping other students or get them with a premium plan
Community
Ask the community for help and clear up your study doubts
Discover the best universities in your country according to Docsity users
Free resources
Download our free guides on studying techniques, anxiety management strategies, and thesis advice from Docsity tutors
Fda v Brown and Williamson, Cosmetic Act, Authority to Regulate, Asserted Jurisdiction, Smokeless Tobacco, Promotion, Advertisers, Summary Judgement, Therapeutic Benefit, Overstepped Its Authority. Case study for law students.
Typology: Study Guides, Projects, Research
1 / 2
This page cannot be seen from the preview
Don't miss anything!
Argued: December 1, 1999 Decided: March 21, 2000
Subjects: Economic Activity: Consumer Protection
Facts of the Case
he Food, Drug, and Cosmetic Act (FDCA) grants the Food and Drug Administration (FDA) the authority to regulate, among other items, "drugs" and "devices." In 1996, the FDA asserted jurisdiction to regulate tobacco products, concluding that, under the FDCA, nicotine is a "drug" and cigarettes and smokeless tobacco are "devices" that deliver nicotine to the body. Accordingly, the FDA promulgated regulations governing tobacco products' promotion, labeling, and accessibility to children and adolescents. Brown & Williamson Tobacco Corporation, and a group of tobacco manufacturers, retailers, and advertisers, filed suit challenging the FDA's regulations. Brown moved for summary judgement on the ground that the FDA lacked the jurisdiction to regulate tobacco products as customarily marketed, or without manufacturer claims of therapeutic benefit. The District Court ruled that the FDA had jurisdiction over tobacco as a device, but that the agency had overstepped its authority in attempting to restrict tobacco advertising. In reversing, the Court of Appeals held that Congress had not granted the FDA jurisdiction to regulate tobacco products. The court found that the FDA's definition of tobacco as a device was flawed because the agency could not prove that the impact of tobacco products on the body was "intended" under the act.
Question Presented
Does the Food and Drug Administration have the authority to regulate tobacco products as "drugs" and "devices" under the Food, Drug, and Cosmetic Act?
Conclusion
No. In a 5-4 opinion delivered by Justice Sandra Day O'Connor, the Court held that "Congress has not given the FDA the authority to regulate tobacco products as customarily marketed." The ruling was based on the FDCA as a whole and in conjunction with Congress' subsequent tobacco-specific legislation. "By no means do we question the seriousness of the problem that the FDA has sought to address," Justice O'Connor wrote for the majority. Nonetheless, Justice O' Connor wrote, "Congress, for better or for worse, has created a distinct regulatory scheme for tobacco products, squarely rejected proposals to give the FDA jurisdiction over tobacco, and repeatedly acted to preclude any agency from exercising significant policymaking authority in the area."